Sign In

Login

Password

Forgot Password ? Sign Up

Afatinib (Vietnamese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Afatinib" in Vietnamese language version.

refsWebsite
Global rank Vietnamese rank
6nih.gov
4th place
7th place
4doi.org
2nd place
2nd place
1tga.gov.au
3,984th place
5,470th place
1medicines.org.uk
3,823rd place
5,469th place
1web.archive.org
1st place
1st place
1europa.eu
68th place
114th place
1medscape.com
719th place
1,344th place

doi.org

  • Vavalà, T (2017). “Role of afatinib in the treatment of advanced lung squamous cell carcinoma”. Clinical pharmacology: advances and applications. 9: 147–157. doi:10.2147/CPAA.S112715. PMID 29225480.
  • Li (2008). “BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models”. Oncogene. 27: 4702–4711. doi:10.1038/onc.2008.109. PMC 2748240. PMID 18408761.
  • Yang, JC; Wu, YL; Schuler, M; Sebastian, M; Popat, S; Yamamoto, N; Zhou, C; Hu, CP; O'Byrne, K; Feng, J; Lu, S; Huang, Y; Geater, SL; Lee, KY; Tsai, CM; Gorbunova, V; Hirsh, V; Bennouna, J; Orlov, S; Mok, T; Boyer, M; Su, WC; Lee, KH; Kato, T; Massey, D; Shahidi, M; Zazulina, V; Sequist, LV (tháng 2 năm 2015). “Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials”. The Lancet Oncology. 16 (2): 141–51. doi:10.1016/s1470-2045(14)71173-8. PMID 25589191.
  • Kobayashi, Y (2015). “EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs”. Clin Cancer Res. 21 (23): 5305–13. doi:10.1158/1078-0432.CCR-15-1046. PMID 26206867.

europa.eu

ema.europa.eu

medicines.org.uk

medscape.com

reference.medscape.com

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Vavalà, T (2017). “Role of afatinib in the treatment of advanced lung squamous cell carcinoma”. Clinical pharmacology: advances and applications. 9: 147–157. doi:10.2147/CPAA.S112715. PMID 29225480.
  • Li (2008). “BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models”. Oncogene. 27: 4702–4711. doi:10.1038/onc.2008.109. PMC 2748240. PMID 18408761.
  • Yang, JC; Wu, YL; Schuler, M; Sebastian, M; Popat, S; Yamamoto, N; Zhou, C; Hu, CP; O'Byrne, K; Feng, J; Lu, S; Huang, Y; Geater, SL; Lee, KY; Tsai, CM; Gorbunova, V; Hirsh, V; Bennouna, J; Orlov, S; Mok, T; Boyer, M; Su, WC; Lee, KH; Kato, T; Massey, D; Shahidi, M; Zazulina, V; Sequist, LV (tháng 2 năm 2015). “Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials”. The Lancet Oncology. 16 (2): 141–51. doi:10.1016/s1470-2045(14)71173-8. PMID 25589191.
  • Kobayashi, Y (2015). “EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs”. Clin Cancer Res. 21 (23): 5305–13. doi:10.1158/1078-0432.CCR-15-1046. PMID 26206867.

dailymed.nlm.nih.gov

ncbi.nlm.nih.gov

tga.gov.au

ebs.tga.gov.au

web.archive.org